Target
Nociceptin receptor
Ligand
BDBM50296843
Substrate
n/a
Meas. Tech.
ChEMBL_582620 (CHEMBL1054183)
EC50
3.1±n/a nM
Citation
 Nishimura, HLi, JIsozaki, KOkada, KMatsushima, ANose, TCosta, TShimohigashi, Y Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activation. Bioorg Med Chem 17:5683-7 (2009) [PubMed]  Article 
Target
Name:
Nociceptin receptor
Synonyms:
Nociceptin/Orphanin FQ, NOP receptor | Nociceptin/mu opioid receptor | OPRX_RAT | Oor | Oprl | Oprl1
Type:
Enzyme Catalytic Domain
Mol. Mass.:
40531.08
Organism:
RAT
Description:
Nociceptin/Orphanin FQ, NOP receptor 0 RAT::P35370
Residue:
367
Sequence:
MESLFPAPYWEVLYGSHFQGNLSLLNETVPHHLLLNASHSAFLPLGLKVTIVGLYLAVCIGGLLGNCLVMYVILRHTKMKTATNIYIFNLALADTLVLLTLPFQGTDILLGFWPFGNALCKTVIAIDYYNMFTSTFTLTAMSVDRYVAICHPIRALDVRTSSKAQAVNVAIWALASVVGVPVAIMGSAQVEDEEIECLVEIPAPQDYWGPVFAICIFLFSFIIPVLIISVCYSLMIRRLRGVRLLSGSREKDRNLRRITRLVLVVVAVFVGCWTPVQVFVLVQGLGVQPGSETAVAILRFCTALGYVNSCLNPILYAFLDENFKACFRKFCCASSLHREMQVSDRVRSIAKDVGLGCKTSETVPRPA
  
Inhibitor
Name:
BDBM50296843
Synonyms:
CHEMBL555757 | FGGFTGARKSARKRWNQ
Type:
Small organic molecule
Emp. Form.:
C87H135N31O22
Mol. Mass.:
1967.1973
SMILES:
C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O |r,wU:1.1,73.75,89.90,42.44,109.110,26.27,131.134,58.59,3.3,wD:78.79,7.15,47.48,98.99,123.126,67.68,(7.43,-25.86,;8.76,-26.64,;10.1,-25.88,;8.75,-28.18,;7.41,-28.94,;6.08,-28.16,;6.09,-26.62,;4.74,-28.93,;4.73,-30.47,;6.06,-31.24,;6.05,-32.78,;7.37,-33.56,;8.72,-32.79,;8.72,-31.24,;7.4,-30.48,;3.41,-28.15,;2.08,-28.91,;2.07,-30.45,;.75,-28.13,;-.59,-28.9,;-1.92,-28.12,;-1.91,-26.58,;-3.26,-28.88,;-4.59,-28.1,;-5.93,-28.87,;-5.94,-30.41,;-7.25,-28.09,;-8.59,-28.85,;-7.24,-26.55,;-8.57,-25.77,;-8.57,-24.23,;-9.89,-23.45,;-11.24,-24.21,;-11.25,-25.76,;-9.91,-26.53,;10.08,-28.96,;10.07,-30.5,;11.42,-28.19,;12.75,-28.97,;14.08,-28.21,;14.09,-26.67,;15.41,-28.99,;16.75,-28.22,;16.76,-26.68,;18.08,-29,;18.07,-30.54,;19.42,-28.24,;20.75,-29.02,;20.74,-30.56,;19.4,-31.32,;19.39,-32.86,;18.06,-33.62,;18.05,-35.16,;16.71,-35.92,;19.38,-35.94,;22.09,-28.25,;22.1,-26.71,;23.42,-29.03,;24.75,-28.27,;24.76,-26.73,;26.1,-25.97,;26.11,-24.43,;27.45,-23.66,;27.46,-22.12,;26.08,-29.05,;26.07,-30.59,;27.42,-28.28,;28.75,-29.06,;28.74,-30.6,;27.4,-31.36,;30.09,-28.3,;30.1,-26.76,;31.42,-29.08,;32.76,-28.31,;32.77,-26.77,;34.08,-29.09,;34.07,-30.63,;35.42,-28.33,;36.75,-29.11,;36.74,-30.65,;35.41,-31.41,;35.4,-32.95,;34.06,-33.71,;34.05,-35.25,;32.72,-36.01,;35.38,-36.03,;38.09,-28.34,;38.1,-26.8,;39.42,-29.12,;40.76,-28.36,;40.77,-26.82,;42.11,-26.06,;42.12,-24.52,;43.46,-23.75,;43.47,-22.21,;42.09,-29.14,;42.08,-30.68,;43.43,-28.37,;44.75,-29.15,;44.75,-30.69,;43.41,-31.45,;43.41,-32.99,;42.07,-33.74,;42.06,-35.28,;40.73,-36.04,;43.39,-36.05,;46.09,-28.39,;46.1,-26.85,;47.42,-29.17,;48.76,-28.4,;48.77,-26.86,;50.1,-26.1,;51.49,-26.73,;52.52,-25.6,;51.76,-24.27,;52.25,-22.82,;51.23,-21.68,;49.72,-21.99,;49.25,-23.44,;50.26,-24.58,;50.09,-29.18,;50.08,-30.72,;51.43,-28.43,;52.76,-29.2,;52.75,-30.74,;54.08,-31.52,;55.42,-30.76,;54.08,-33.06,;54.1,-28.44,;54.11,-26.9,;55.42,-29.22,;56.76,-28.46,;56.77,-26.92,;58.11,-26.15,;58.12,-24.61,;56.79,-23.84,;59.46,-23.85,;58.09,-29.23,;59.43,-28.47,;58.09,-30.77,)|
Structure:
Search PDB for entries with ligand similarity: